A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy

Brief description of study

Some people with HCM have obstructive HCM (oHCM) and other participants have non-obstructive HCM (nHCM). HCM is a condition in which the heart muscle becomes abnormally thickened, which can sometimes block the blood flow out the heart and causes the heart muscle to work harder to pump blood to the body (increased heart pumping function). CK-3773274 is designed to reduce heart pumping function. This is the first time study drug called CK-3773274 will be studied in participants who have HCM, but it already has been studied in healthy volunteers. The purpose of this study is to evaluate the effects of CK3773274, to learn how well it is tolerated in patients with HCM and if it causes any side effects. The study drug may reduce symptoms of your HCM by reducing heart pumping function. Additionally, this study will examine how the study drug works for people that are already taking the medicine, disopyramide.


Clinical Study Identifier: s19-01518
ClinicalTrials.gov Identifier: NCT04219826
Principal Investigator: Mark V. Sherrid.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.